|
?:abstract
|
-
INTRODUCTION AND AIM SARS-CoV-2 infection was declared as a pandemic by World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already passed those of many previous epidemics. A wide variety of treatment options are being considered for COVID-19, but there is still no definitive treatment or vaccine. This review aims to explain the background of the convalescent plasma treatment and its relations with COVID-19 immunity, to define the ideal treatment procedures and to reveal present and future perspectives in the light of rapidly growing data. Immunological basis of COVID-19 associated immune response and convalescent plasma as a treatment option: Since it has been shown that the impaired immune response of the host is one of the most important factors that increase the severity of the infection, treatment strategies to suppress aberrant immune activation are being dwelled on. Convalescent/immune plasma, which is derived from recently recovered patients and contains neutralizing antibodies and many other immune-modulatory substances, seems to be the most convenient strategy to restore normal immune function considering the fast-spreading nature of the ongoing pandemic. Conclusion and future perspectives: Even though mechanisms of action of plasma therapy are not fully delineated, it has been shown that it could lead to a reduction in mortality since other alternatives such as monoclonal antibodies or SARS-CoV-2 hyper immunoglobulin require much more time and effort to be developed.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}